CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has identified son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12D mutant) interaction inhibitors reported to be useful for the treatment of cancer, cardiofaciocutaneous syndrome, Costello syndrome, neurofibromatosis type 1, Noonan syndrome and Legius syndrome (neurofibromatosis type 1-like syndrome).